Kimberly Wilkinson of Avation Medical awarded Top 25 Healthcare Tech Leaders of Houston 2022

Oct 4, 2022

Avation Medical’s Kimberly Wilkinson was recognized by The Healthcare Technology Report in its recent announcement of The Top 25 Healthcare Tech Leaders of Houston, TX for 2022. As Senior Director of Clinical Operations, Kimberly leads Avation Medical’s clinical trial strategy to demonstrate the efficacy, safety, and ease of use of the Company’s game-changing digitally enabled wearable neuromodulation therapy and behavioral support platform to treat overactive bladder and urge urinary incontinence. With over 20 years of experience in the pharmaceutical and medical device industries, Kimberly has demonstrated a passion for ensuring that effective and safe medical technologies that can meaningfully improve care, are brought to market.

Please join us in celebrating Kimberly Wilkinson of Avation Medical, as one of the Top 25 Healthcare Technology Leaders of Houston for 2022.

View More

About Avation Medical

Avation Medical is an innovative advanced neuromodulation and digital health company pioneering closed-loop, patient-friendly, wearable neuromodulation therapies that deliver personalized therapy based on the patient’s own physiologic response. The Company’s intelligent wearable therapies objectively confirm activation of the target nerve and make neuromodulation technology accessible to millions of patients across a variety of clinical applications by eliminating the need for surgery, needles and permanent implants and shifting therapy into the home environment.

The Company’s wearable bladder therapy and digital health system is available for investigational use only and is not FDA cleared.

Corporate Contact

Jackie Gerberry
Senior Director, Finance
Jgerberry@Avation.com
www.Avation.com

Avation CEO, Jill Schiaparelli, to join all-female panel with executives from Medtronic, Danaher, and other distinguished life science companies to discuss digital health innovations at BioMedDevice Boston

July 11, 2022

Medical Devices and Diagnostic Industries announced a keynote panel discussion at BIOMedevice Boston to occur on Thu, Sep 29, 2022. Six female medical device industry executives will team up to talk about innovations in digital health solutions, Artificial Intelligence, and the regulatory challenges these innovations may face. The event will be moderated by Maria Shepherd, president of Medi-Vantage and co-founder of MedExecWomen. The panel, with Shepherd moderating, includes Jill Dooling, vice president of Strategic Accounts at Vapotherm, Sara Kehoe, Senior Director, Clinical Insights at Danaher Diagnostics, Teresa Prego, Chief Commercial Officer at Nile, Mira Sahney, President, Pelvic Health at Medtronic, and Jill Schiaparelli, CEO at Avation Medical. The session, sponsored by MedExec Women, will be held Thursday, Sept. 29, from 9:15 to 10:15 a.m. on the Center Stage.

View More

About Avation Medical

Avation Medical is an innovative advanced neuromodulation and digital health company pioneering closed-loop, patient-friendly, wearable neuromodulation therapies that deliver personalized therapy based on the patient’s own physiologic response. The Company’s intelligent wearable therapies objectively confirm activation of the target nerve and make neuromodulation technology accessible to millions of patients across a variety of clinical applications by eliminating the need for surgery, needles and permanent implants and shifting therapy into the home environment.

The Company’s wearable bladder therapy and digital health system is available for investigational use only and is not FDA cleared.

Corporate Contact

Jackie Gerberry
Senior Director, Finance
Jgerberry@Avation.com
www.Avation.com

Avation Medical CEO, Jill Schiaparelli, awarded one of the Top 25 Women Leaders in Consumer Health Tech for 2022 by The Healthcare Technology Report

July 11, 2022

Avation Medical is proud to share that our CEO, Jill Schiaparelli, has been named one of the Top 25 Women Leaders in Consumer Health Tech for 2022 by The Healthcare Technology Report. This year’s awardees lead companies across the healthcare technology industry. What they all have in common is their dedication to driving their companies’ growth and competitiveness in the markets they serve. Please join us in celebrating Jill and all the other accomplished women leaders who received this honor for advancing medical device innovation and patient care. #topwomanleader #femalestrong #medicaldevices #womenleaders #ceo.

View More

About Avation Medical

Avation Medical is an innovative advanced neuromodulation and digital health company pioneering closed-loop, patient-friendly, wearable neuromodulation therapies that deliver personalized therapy based on the patient’s own physiologic response. The Company’s intelligent wearable therapies objectively confirm activation of the target nerve and make neuromodulation technology accessible to millions of patients across a variety of clinical applications by eliminating the need for surgery, needles and permanent implants and shifting therapy into the home environment.

The Company’s wearable bladder therapy and digital health system is available for investigational use only and is not FDA cleared.

Corporate Contact

Jackie Gerberry
Senior Director, Finance
Jgerberry@Avation.com
www.Avation.com

Avation Medical to present clinical evidence on pioneering wearable neuromodulation and digital behavioral support system at the American Urogynecologic Society (AUGS) 2022 Scientific Meeting

Dr. Colin Goudelocke, investigator in the "FreeOAB Study", will present the results of Avation Medical’s recent clinical trial evaluating the safety and efficacy of a novel at-home wearable neuromodulation and digital behavioral support system to treat the symptoms of OAB and UUI at the American Urogynecologic Society (AUGS) and International Urogynecological Association (IUGA) 2022 Scientific Meeting in Austin, Texas June 14-17, 2022

Columbus, Ohio, June 10, 2022

Avation Medical, an innovative neuromodulation and digital health company pioneering a wearable platform to treat the symptoms of overactive bladder (OAB) and urge urinary incontinence (UUI), today announced that Dr. Colin Goudelocke, investigator in the FreeOAB clinical study and urologist at Ochsner Health in New Orleans, will present evidence in support of the safety and efficacy of a new therapy and digital behavioral support system to treat the symptoms of overactive bladder (OAB) and urge urinary incontinence (UUI).

The Vivally™ System is a wearable bladder control therapy and digital health system utilizing neuromodulation to treat patients with the chronic conditions of overactive bladder (OAB) and urge urinary incontinence (UUI) and their associated symptoms including urinary urgency, urinary frequency, and urge urinary incontinence, without the need for surgery, permanent implants, or drugs. The non-invasive therapy and digital health system is intended to provide personalized treatment with the ability to conduct therapy at home, in as little as 30 minutes per week. The Vivally System features patented closed-loop control technology that uses the patient’s own physiologic response to objectively confirm activation of the tibial nerve and continuously monitor nerve recruitment, automatically adjusting the stimulation within a personalized therapeutic range set by the physician, for each patient, to ensure both comfort, and optimal therapeutic output.

The Vivally System is prescribed by a physician following a brief clinical screening and personalization to ensure that the therapy is tailored to each patient and provides a comfortable experience. The Vivally System Patient Kit includes a Stimulator with rechargeable battery, wearable garment, gel cushions, and accessories. Its digital components include a mobile app that allows patients to control and monitor therapy, symptoms, and other activities, and a HIPAA compliant cloud-based web portal for physicians and patients that collects therapy history, bladder events and patient behavior, allowing users to easily track the treatment progress and enabling additional therapy adjustments when appropriate.

Jill Schiaparelli, Avation’s CEO commented “Avation Medical is a strong team of professionals that is committed to making neuromodulation more accessible to patients suffering from chronic conditions like OAB through its wearable therapy and digitally enabled behavioral support platform. We are honored that Dr. Goudelocke will present this groundbreaking evidence on behalf of the investigators.”

Vivally is currently available for investigational use only and is not yet FDA cleared.

Details of the clinical evidence presented at AUGS can be found here.

Corporate Contact

Jackie Gerberry
Senior Director
Jgerberry@Avation.com
www.Avation.com

Avation Medical Announces Appointment of Chief Marketing Officer to Executive Leadership Team

Avation Medical appoints Darren Wennen, a medical industry veteran, as Chief Marketing Officer in anticipation of commercialization of its wearable neuromodulation system to treat OAB and UUI.

Columbus, Ohio, April 13, 2022

Avation Medical, an innovative neuromodulation and digital health company pioneering a wearable system to treat the symptoms of overactive bladder (OAB) and urge urinary incontinence (UUI), today announced the appointment of Darren Wennen as its Chief Marketing Officer. He will be responsible for all aspects of marketing, sales operations and customer care as the Company prepares to bring its novel wearable therapy and digital support system to market.

“I am thrilled to welcome Darren to Avation Medical. His commercial experience and track record of growth is the ideal addition to our team as we prepare to launch our category-changing technology for patients suffering from OAB and UUI,” said Jill Schiaparelli, Avation’s CEO. “Darren joins a strong team of professionals at Avation that is committed to making neuromodulation more accessible to patients suffering from chronic conditions through its wearable therapy and digitally enabled behavioral support platform.”

“I am very excited about the potential for Avation’s easy-to-use wearable therapy system,” added Mr. Wennen. “The 42 million Americans with OAB and UUI have sent a clear message that they want an effective treatment option that does not require surgery, permanent implants or the side-effects of medication. Our system combines non-invasive neuromodulation therapy with a digitally enabled behavioral support system, offering patients a new option that is effective, convenient, and safe.”

Mr. Wennen brings to Avation Medical a demonstrated history of successful product launches and sales growth. Most recently, Mr. Wennen served as VP of Marketing and Clinical Affairs, as well as SVP of Commercial Operations, for Tactile Medical (NASDAQ: TCMD), where he helped to develop an underserved, reimbursement driven DME wearable market in lymphedema, to grow the company to over $200 million in sales and to complete an IPO on NASDAQ. Earlier in his career, Mr. Wennen held leadership roles with Stryker Orthopedics, Gyrus/ACMI (now Olympus), St. Jude Medical (now Abbott) and Sterilmed (a J&J Company). Mr. Wennen holds an MBA in marketing and international finance from the University of St. Thomas (St. Paul, MN), and a bachelor’s degree from the University of Minnesota.

About Avation Medical

Avation Medical is an innovative neuromodulation and digital health company with a mission to make neuromodulation more accessible to patients across a variety of clinical conditions by eliminating the need for surgery, permanent implants and the side-effects of medications and shifting treatment to the home environment. The Company’s novel platform combines non-invasive neuromodulation therapy with digital health tools to offer a complete therapy and support system across a range of chronic conditions. The Company’s intelligent wearable therapy objectively confirms activation of the target nerve, sets a personalized therapeutic range for each patient, and delivers clinically effective therapy in just 30 minutes. The Company’s first product, a wearable neuromodulation and digitally enabled behavior support system for OAB and UUI, is currently available for investigational use only and is not FDA cleared.

Corporate Contact

Jackie Gerberry
Senior Director
Jgerberry@Avation.com
www.Avation.com

Avation Medical Announces the Appointment of Industry Veterans to Board of Directors

Avation Medical adds two board members as it moves to commercialize its first product

Columbus, Ohio, December 8, 2021

Avation Medical, an innovative advanced neuromodulation and digital health company pioneering closed-loop, wearable neuromodulation therapies that eliminate the need for surgery and implants, announced today the appointment of two highly experienced medical device and health care executives to its Board of Directors. The two new Board members bring a wealth of commercialization experience as the Company moves quickly to bring its first product to market.

Renee Selman, an accomplished pharmaceutical, medical device and healthcare services senior executive and former Worldwide President, Women’s Health and Urology for Ethicon, a Johnson & Johnson Company, has joined the Board as an Independent Director. Renee brings extensive global and domestic experience in the healthcare industry including commercialization of international products, market development, and strategic partnership development. Ms. Selman currently serves on the boards of FEMSelect and Hunterdon Medical System.

Raymond Huggenberger, a senior business leader with deep experience in innovative medical technology spanning more than 20 years of successful sales, marketing, and general management experience in highly competitive industries, has been appointed as an Independent Director. Ray previously served as the President and CEO of Inogen, Inc., and currently serves on the boards of several publicly traded medical device companies including Tactile Systems Technology, Inc. (TCMD), Inogen, Inc. (INGN) and Intricon Micromedical Technology (IIN) as well as several privately held companies. He also serves in an advisory capacity to Arboretum Ventures.

“Renee and Ray bring a wealth of strategic experience to Avation Medical which will be essential as we work to launch our category-changing, wearable and self-adjusting bladder modulation and digital health system to help the more than 40 million adults with overactive bladder (OAB) and urge incontinence that do not want invasive surgical procedures or the side effects of medications,” said Jill Schiaparelli, President and CEO of Avation Medical.

“There remains an enormous need for patient-friendly, wearable neuromodulation therapy. I am honored to join the Avation Medical Board of Directors and work with the Company’s talented team as we work to bring innovative technologies to the market,” said Ms. Selman. “Avation is a true innovator in the industry, and I look forward to supporting its ongoing work to revolutionize the science of self-adjusting, wearable neuromodulation and digital health therapies.”

Mr. Huggenberger commented, "I am excited to join Avation Medical’s board and work with the Company to make neuromodulation therapy surgery-free and more accessible to patients across a variety of clinical conditions. The Company's pioneering technology is a game-changer and will provide a new solution to the millions of OAB patients who desire surgery-free and drug-free treatment options.”

In addition to Renee and Ray, the Board includes Dr. Thomas Shehab, Managing Partner, Arboretum Ventures; Kevin Wasserstein, Neurotechnology Innovations Management; and Jill Schiaparelli, President and CEO of Avation Medical.

About Avation Medical

Avation Medical is an innovative advanced neuromodulation and digital health company pioneering closed-loop, patient-friendly, wearable neuromodulation therapies that deliver personalized therapy based on the patient’s own physiologic response. The Company’s intelligent wearable therapies objectively confirm activation of the target nerve and make neuromodulation technology accessible to millions of patients across a variety of clinical applications by eliminating the need for surgery, needles and permanent implants and shifting therapy into the home environment.

The Company’s wearable bladder therapy and digital health system is available for investigational use only and is not FDA cleared.

Corporate Contact

Jackie Gerberry
Senior Director, Finance
Jgerberry@Avation.com
www.Avation.com